<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04574843</url>
  </required_header>
  <id_info>
    <org_study_id>990631</org_study_id>
    <nct_id>NCT04574843</nct_id>
  </id_info>
  <brief_title>Middle Meningeal Artery Embolization With Liquid Embolic Agent for Treatment of Chronic Subdural Hematoma</brief_title>
  <official_title>Middle Meningeal Artery Embolization With Liquid Embolic Agent for Treatment of Chronic Subdural Hematoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mashhad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mashhad University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the clinical and imaging outcome of middle meningeal artery (MMA)&#xD;
      embolization with liquid embolic agent for treatment of chronic subdural hematoma (CSDH)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective one arm trial designed to assess the safety and efficacy of MMA&#xD;
      embolization with liquid embolic agents (onyx/squid/Phil) as the main treatment of CSDH.&#xD;
&#xD;
      The subjects are enrolled in the study according to inclusion and exclusion criteria. Imaging&#xD;
      and clinical presentations of patients are recorded. Within 48 hours of embolization,&#xD;
      patients are assessed with clinical examination and with a brain CT scan to evaluate in any&#xD;
      change in their symptoms and CSDH volume. 2-4 weeks after embolization, patients are&#xD;
      evaluated in clinic for any change in their symptoms and signs. 60 days after embolization&#xD;
      patients are examined clinically and are assessed for SDH volume change in CT scan and MRI.&#xD;
&#xD;
      If there is any significant increase in CSDH volume or any deterioration of patient,&#xD;
      evacuation of hematoma is considered.&#xD;
&#xD;
      MMA embolization is performed under general anesthesia using biplane or monoplane&#xD;
      angiography. Femoral or radial accesses are used. Guiding catheter is advanced into external&#xD;
      carotid artery in corresponding side. The corresponding MMA is catheterized distally by&#xD;
      micro-catheter and is embolized by liquid embolic agents. Patients are discharge next day if&#xD;
      they are stable.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of CSDH regression</measure>
    <time_frame>60 dyas</time_frame>
    <description>Volume reduction of CSDH in follow-up imaging (CT/MRI) 60 days after embolization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of CSDH progression or recurrence</measure>
    <time_frame>60 days</time_frame>
    <description>Increase in volume of CSDH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new neurological deficit (ND)</measure>
    <time_frame>60 days</time_frame>
    <description>ND includes: dementia, memory loss, cognitive problems, monoparesis/hemiparesis, cranial nerve paresis, dysphasia/aphasia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of Death</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new ischemic stroke</measure>
    <time_frame>60 days</time_frame>
    <description>new ischemia in imaging (DWI/MRI or CT scan) within 60 days of operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of myocardial infarction/myocardial ischemia</measure>
    <time_frame>60 days</time_frame>
    <description>new ischemic heart attack within 60 days of operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of embolization complication in brain</measure>
    <time_frame>48 hours</time_frame>
    <description>cranial nerve palsy (especially VII), vision loss (ophthalmic/retinal artery occlusion), ...</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of embolization complication out of brain</measure>
    <time_frame>15 days</time_frame>
    <description>puncture hematoma, major artery dissection, new renal failure, ...</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Subdural Hematoma</condition>
  <arm_group>
    <arm_group_label>Embolization arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Embolization of middle meningeal artery Device: Onyx, squid, Phil</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Embolization of MMA</intervention_name>
    <description>embolization of MMA with one of following liquid embolic agents (Onyx-Squid-Phil)</description>
    <arm_group_label>Embolization arm</arm_group_label>
    <other_name>Onyx</other_name>
    <other_name>Squid</other_name>
    <other_name>Phil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. patients diagnosed chronic or subacute subdural hematoma&#xD;
&#xD;
          2. Patients had symptoms/signs associated with chronic or subacute subdural hematoma:&#xD;
             severe headache, hemiparesis/monoparesis, dementia, aphasia/dysphasia, loss of&#xD;
             consciousness, ...&#xD;
&#xD;
          3. Asymptomatic large chronic/subacute hematoma after 6-8 weeks of failed conservative&#xD;
             treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. presentation with coma (GCS =&lt; 8)&#xD;
&#xD;
          2. patients needs emergent evacuation of hematoma,&#xD;
&#xD;
          3. patients could not participate in 60 days follow-up&#xD;
&#xD;
          4. pregnant patients&#xD;
&#xD;
          5. acute subdural hematoma&#xD;
&#xD;
          6. contraindication to contrast&#xD;
&#xD;
          7. contradiction to angiography&#xD;
&#xD;
          8. difficult access to MMA due to anatomical variation&#xD;
&#xD;
          9. contraindication to liquid embolic agent&#xD;
&#xD;
         10. unmanaged/uncontrollable bleeding disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Humain Baharvahdat, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Neurosurgery, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Humain Baharvahdat, MD</last_name>
    <phone>+98-915-110-0400</phone>
    <email>humainbv@yahoo.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Masoud Pishjoo, MD</last_name>
    <phone>‭+98 915 362 8792‬</phone>
    <email>masoud.pishjoo@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ghaem Hospital, Mashhad University of Medical Sciences</name>
      <address>
        <city>Mashhad</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Humain Baharvahdat, MD</last_name>
      <phone>+98-915-110-0400</phone>
      <email>humainbv@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Ehsan Keykhosravi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mashhad University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Humain Baharvahdat</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>chronic subdural hematoma</keyword>
  <keyword>embolization</keyword>
  <keyword>middle meningeal artery</keyword>
  <keyword>liquid embolic agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematoma, Subdural</mesh_term>
    <mesh_term>Hematoma, Subdural, Chronic</mesh_term>
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

